Development of High Signal Intensity within the Globus Pallidus and Dentate Nucleus following Multiple Administrations of Gadobenate Dimeglumine

References

1. 1.↵
   2. Kanda T,
   3. Ishii K,
   4. Kawaguchi H, et al

   . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270:834–41 doi:10.1148/radiol.13131669 pmid:24475844

   CrossRefPubMed
2. 2.↵
   2. Kanda T,
   3. Fukusato T,
   4. Matsuda M, et al

   . Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015;276:228–32 doi:10.1148/radiol.2015142690 pmid:25942417

   CrossRefPubMed
3. 3.↵
   2. McDonald RJ,
   3. McDonald JS,
   4. Kallmes DF, et al

   . Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 2015;275:772–82 doi:10.1148/radiol.15150025 pmid:25742194

   CrossRefPubMed
4. 4.↵
   2. Errante Y,
   3. Cirimele V,
   4. Mallio CA, et al

   . Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 2014;49:685–90 doi:10.1097/RLI.0000000000000072 pmid:24872007

   CrossRefPubMed
5. 5.↵
   2. Quattrocchi CC,
   3. Mallio CA,
   4. Errante Y, et al

   . Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol 2015;50:470–72 doi:10.1097/RLI.0000000000000154 pmid:25756685

   CrossRefPubMed
6. 6.↵
   2. Radbruch A,
   3. Weberling LD,
   4. Kieslich PJ, et al

   . High-signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evaluation of the macrocyclic gadolinium-based contrast agent gadobutrol. Invest Radiol 2015;50:805–10 doi:10.1097/RLI.0000000000000227 pmid:26523910

   CrossRefPubMed
7. 7.↵
   2. Cao Y,
   3. Huang DQ,
   4. Shih G, et al

   . Signal change in the dentate nucleus on T1-weighted MR images after multiple administrations of gadopentetate dimeglumine versus gadobutrol. AJR Am J Roentgenol 2016;206:414–19 doi:10.2214/AJR.15.15327 pmid:26700156

   CrossRefPubMed
8. 8.↵
   2. Stojanov DA,
   3. Aracki-Trenkic A,
   4. Vojinovic S, et al

   . Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol 2016;26:807–15 doi:10.1007/s00330-015-3879-9 pmid:26105022

   CrossRefPubMed
9. 9.↵
   2. Bjørnerud A,
   3. Vatnehol SA,
   4. Larsson C, et al

   . Signal enhancement of the dentate nucleus at unenhanced MR imaging after very high cumulative doses of the macrocyclic gadolinium-based contrast agent gadobutrol: an observational study. Radiology 2017;285:434–44 doi:10.1148/radiol.2017170391 pmid:28885891

   CrossRefPubMed
10. 10.↵
    2. Radbruch A,
    3. Haase R,
    4. Kieslich PJ, et al

    . No signal intensity increase in the dentate nucleus on unenhanced T1-weighted MR images after more than 20 serial injections of macrocyclic gadolinium-based contrast agents. Radiology 2017;282:699–707 doi:10.1148/radiol.2016162241 pmid:27925871

    CrossRefPubMed
11. 11.↵
    2. Splendiani A,
    3. Perri M,
    4. Marsecano C, et al

    . Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients. Radiol Med 2017 Sep 27. [Epub ahead of print] doi:10.1007/s11547-017-0816-9 pmid:28952018

    CrossRefPubMed
12. 12.↵
    2. Miller JH,
    3. Hu HH,
    4. Pokorney A, et al

    . MRI brain signal intensity changes of a child during the course of 35 gadolinium contrast examinations. Pediatrics 2015;136:e1637–40 doi:10.1542/peds.2015-2222 pmid:26574593

    Abstract/FREE Full Text
13. 13.↵
    2. Roberts DR,
    3. Chatterjee AR,
    4. Yazdani M, et al

    . Pediatric patients demonstrate progressive T1-weighted hyperintensity in the dentate nucleus following multiple doses of gadolinium-based contrast agent. AJNR Am J Neuroradiol 2016;37:2340–47 doi:10.3174/ajnr.A4891 pmid:27469211

    Abstract/FREE Full Text
14. 14.↵
    2. Roberts DR,
    3. Holden KR

    . Progressive increase of T1 signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in the pediatric brain exposed to multiple doses of gadolinium contrast. Brain Dev 2016;38:331–36 doi:10.1016/j.braindev.2015.08.009 pmid:26345358

    CrossRefPubMed
15. 15.↵
    2. Hu HH,
    3. Pokorney A,
    4. Towbin RB, et al

    . Increased signal intensities in the dentate nucleus and globus pallidus on unenhanced T1-weighted images: evidence in children undergoing multiple gadolinium MRI exams. Pediatr Radiol 2016;46:1590–98 doi:10.1007/s00247-016-3646-3 pmid:27282825

    CrossRefPubMed
16. 16.↵
    2. Flood TF,
    3. Stence NV,
    4. Maloney JA, et al

    . Pediatric brain: repeated exposure to linear gadolinium-based contrast material is associated with increased signal intensity at unenhanced T1-weighted MR imaging. Radiology 2017;282:222–28 doi:10.1148/radiol.2016160356 pmid:27467467

    CrossRefPubMed
17. 17.↵
    2. Radbruch A,
    3. Haase R,
    4. Kickingereder P, et al

    . Pediatric brain: no increased signal intensity in the dentate nucleus on unenhanced T1-weighted MR images after consecutive exposure to a macrocyclic gadolinium-based contrast agent. Radiology 2017;283:828–36 doi:10.1148/radiol.2017162980 pmid:28273007

    CrossRefPubMed
18. 18.↵
    2. Tibussek D,
    3. Rademacher C,
    4. Caspers J, et al

    . Gadolinium brain deposition after macrocyclic gadolinium administration: a pediatric case-control study. Radiology 2017;285:223–230 doi:10.1148/radiol.2017161151 pmid:28640695

    CrossRefPubMed
19. 19.↵
    2. Rossi Espagnet MC,
    3. Bernardi B,
    4. Pasquini L, et al

    . Signal intensity at unenhanced T1-weighted magnetic resonance in the globus pallidus and dentate nucleus after serial administrations of a macrocyclic gadolinium-based contrast agent in children. Pediatr Radiol 2017;47:1345–52 doi:10.1007/s00247-017-3874-1 pmid:28526896

    CrossRefPubMed
20. 20.↵
    2. Kanda T,
    3. Osawa M,
    4. Oba H, et al

    . High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 2015;275:803–09 doi:10.1148/radiol.14140364 pmid:25633504

    CrossRefPubMed
21. 21.↵
    2. Radbruch A,
    3. Quattrocchi CC

    . Interpreting signal-intensity ratios without visible T1 hyperintensities in clinical gadolinium retention studies. Pediatr Radiol 2017;47:1688–89 doi:10.1007/s00247-017-3970-2 pmid:28914340

    CrossRefPubMed
22. 22.↵
    2. Radbruch A,
    3. Weberling LD,
    4. Kieslich PJ, et al

    . Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 2015;275:783–91 doi:10.1148/radiol.2015150337 pmid:25848905

    CrossRefPubMed
23. 23.↵
    2. Radbruch A,
    3. Weberling LD,
    4. Kieslich PJ, et al

    . Intraindividual analysis of signal intensity changes in the dentate nucleus after consecutive serial applications of linear and macrocyclic gadolinium-based contrast agents. Invest Radiol 2016;51:683–90 doi:10.1097/RLI.0000000000000308 pmid:27495187

    CrossRefPubMed
24. 24.↵
    2. Ramalho J,
    3. Castillo M,
    4. AlObaidy M, et al

    . High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology 2015;276:836–44 doi:10.1148/radiol.2015150872 pmid:26079490

    CrossRefPubMed
25. 25.↵
    2. Weberling LD,
    3. Kieslich PJ,
    4. Kickingereder P, et al

    . Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after gadobenate dimeglumine administration. Invest Radiol 2015;50:743–48 doi:10.1097/RLI.0000000000000206 pmid:26352749

    CrossRefPubMed
26. 26.↵
    2. Schneider GK,
    3. Stroeder J,
    4. Roditi G, et al

    . T1 signal measurements in pediatric brain: findings after multiple exposures to gadobenate dimeglumine for imaging of nonneurologic disease. AJNR Am J Neuroradiol 2017;38:1799–1806 doi:10.3174/ajnr.A5270 pmid:28642266

    Abstract/FREE Full Text
27. 27.↵
    2. Kanda T,
    3. Oba H,
    4. Toyoda K, et al

    . Brain gadolinium deposition after administration of gadolinium-based contrast agents. Jpn J Radiol 2016;34:3–9 doi:10.1007/s11604-015-0503-5 pmid:26608061

    CrossRefPubMed
28. 28.↵
    2. Cohen J

    . Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 1968;70:213–20 doi:10.1037/h0026256 pmid:19673146

    CrossRefPubMedWeb of Science
29. 29.↵
    2. Landis JR,
    3. Koch GG

    . The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74 doi:10.2307/2529310 pmid:843571

    CrossRefPubMedWeb of Science
30. 30.↵
    2. Cavagna FM,
    3. Maggioni F,
    4. Castelli PM, et al

    . Gadolinium chelates with weak binding to serum proteins: a new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997;32:780–96 doi:10.1097/00004424-199712000-00009 pmid:9406019

    CrossRefPubMed
31. 31.↵
    2. de Haën C,
    3. Cabrini M,
    4. Akhnana L, et al

    . Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 1999;23(Suppl 1):S161–68 doi:10.1097/00004728-199911001-00021 pmid:10608412

    CrossRefPubMed
32. 32.↵
    2. Pintaske J,
    3. Martirosian P,
    4. Graf H, et al

    . Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006;41:213–21 doi:10.1097/01.rli.0000197668.44926.f7 pmid:16481903

    CrossRefPubMed
33. 33.↵
    2. Shen Y,
    3. Goerner FL,
    4. Snyder C, et al

    . T1 relaxivities of gadolinium-based magnetic resonance contrast agents in human whole blood at 1.5, 3, and 7 T. Invest Radiol 2015;50:330–38 doi:10.1097/RLI.0000000000000132 pmid:25658049

    CrossRefPubMed
34. 34.↵
    2. Kirchin MA,
    3. Pirovano GP,
    4. Spinazzi A

    . Gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 1998;33:798–809 doi:10.1097/00004424-199811000-00003 pmid:9818314

    CrossRefPubMed
35. 35.↵
    2. Bruce R,
    3. Wentland AL,
    4. Haemel AK, et al

    . Incidence of nephrogenic systemic fibrosis using gadobenate dimeglumine in 1423 patients with renal insufficiency compared with gadodiamide. Invest Radiol 2016;51:701–05 doi:10.1097/RLI.0000000000000259 pmid:26885631

    CrossRefPubMed
36. 36.↵
    2. Nandwana SB,
    3. Moreno CC,
    4. Osipow MT, et al

    . Gadobenate dimeglumine administration and nephrogenic systemic fibrosis: is there a real risk in patients with impaired renal function? Radiology 2015;276:741–47 doi:10.1148/radiol.2015142423 pmid:25875973

    CrossRefPubMed
37. 37.↵
    2. Martin DR,
    3. Kalb B,
    4. Mittal A, et al

    . No Incidence of nephrogenic systemic fibrosis after gadobenate dimeglumine administration in patients undergoing dialysis or those with severe chronic kidney disease. Radiology 2017 Jul 21. [Epub ahead of print] doi:10.1148/radiol.2017170102 pmid:28731375

    CrossRefPubMed
38. 38.↵
    2. Frenzel T,
    3. Apte C,
    4. Jost G, et al

    . Quantification and assessment of the chemical form of residual gadolinium in the brain after repeated administration of gadolinium-based contrast agents: comparative study in rats. Invest Radiol 2017;52:396–404 doi:10.1097/RLI.0000000000000352 pmid:28125438

    CrossRefPubMed
39. 39.↵
    2. McDonald RJ,
    3. McDonald JS,
    4. Dai D, et al

    . Comparison of gadolinium concentrations within multiple rat organs after intravenous administration of linear versus macrocyclic gadolinium chelates. Radiology 2017;285:536–45 doi:10.1148/radiol.2017161594 pmid:28640692

    CrossRefPubMed
40. 40.↵
    2. Frenzel T,
    3. Lengsfeld P,
    4. Schirmer H, et al

    . Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008;43:817–28 doi:10.1097/RLI.0b013e3181852171 pmid:19002053

    CrossRefPubMedWeb of Science